Qiagen signs diagnostic biomarker deals

Qiagen, a Netherlands-based bioassay company, is developing new cancer biomarker assays after acquiring rights to genes and biomarkers. In agreements with Insight Genetics and Personal Genome Diagnostics, Qiagen has gained the diagnostic rights for the gene coding for ALK (anaplastic lymphoma kinase), which has potential as a target for lung cancer treatment, and IDH1/IDH2 mutations, which may have uses in brain gliomas, acute myelogenous leukemia and other cancers. Qiagen will work with the two companies to develop companion diagnostics for use with new drugs in development and once they reach the market. Press release | Article

Suggested Articles

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.